HC Wainwright restated their buy rating on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research note issued to investors on Wednesday, AnalystRatings.com reports. The firm currently has a $15.50 price target on the biotechnology company’s stock.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Pluristem Therapeutics from a hold rating to a buy rating and set a $4.25 price target on the stock in a research note on Thursday, October 17th. LADENBURG THALM/SH SH started coverage on shares of Pluristem Therapeutics in a research note on Monday, July 22nd. They set a buy rating on the stock. Finally, ValuEngine downgraded shares of Pluristem Therapeutics from a buy rating to a hold rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $9.25.
PSTI traded up $0.03 on Wednesday, hitting $3.23. 23,200 shares of the company were exchanged, compared to its average volume of 72,100. The company has a current ratio of 2.74, a quick ratio of 3.23 and a debt-to-equity ratio of 0.07. Pluristem Therapeutics has a fifty-two week low of $3.17 and a fifty-two week high of $11.90. The business’s fifty day moving average is $3.55 and its 200 day moving average is $2.47.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Article: What is meant by a buy rating?
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.